Study summary · research use only
Obesity drugs in clinical development
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review article surveys anti-obesity drugs in clinical development. The authors group them into centrally acting agents (such as radafaxine, rimonabant, APD-356, oleoyl-estrone), drugs targeting peripheral satiety signals (glucagon-like peptide-1 agents exenatide, exenatide-LAR, and liraglutide; peptide YY agents; amylin agent pramlintide), fat-absorption blockers (cetilistat, GT-389255), and a human growth hormone fragment (AOD-9604) said to increase adipose-tissue breakdown. They note that of these only rimonabant had completed phase III trials, and provide an overview of the agents under development. No individual outcome data are reported.
Abstract
A number of anti-obesity drugs are currently undergoing clinical development. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1 (exenatide, exenatide-LAR and liraglutide), peptide YY (intranasal PYY3-36 and AC-162325) and amylin (pramlintide); (iii) drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and (iv) a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown. Of these, only rimonabant has got as far as completing phase III clinical trials. This review will provide an overview of the most prominent drugs currently undergoing clinical development as potential anti-obesity therapies.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.